© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
December 13, 2009
Anthracycline chemotherapy plus trastuzumab outperformed anthracycline alone, and performed similarly to a non-anthracycline regimen in breast cancer patients.
December 12, 2009
Updated results confirm that addition of bevacizumab to docetaxel as first-line breast cancer treatment improves survival and response rates.
Sorafenib showed promise when combined with chemotherapy for locally advanced or metastatic breast cancer.
Adding bevacizumab to chemotherapy improved survival compared with chemotherapy alone in breast cancer patients.
Noah Rindos, MD, Talks Fibroids, Adenomyosis and Pregnancy
Kausik Ray, MD: A Risk-Based Look at LDL Cholesterol Lowering
Jennifer Green, MD: Outcomes, Impact of SGLT2i, GLP-1 RA Combination Therapy